Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Prediction of Terpenoid Toxicity Based on a Quantitative Structure-Activity Relationship Model.

Perestrelo R, Silva C, Fernandes MX, Câmara JS.

Foods. 2019 Dec 1;8(12). pii: E628. doi: 10.3390/foods8120628.

2.

Selenocoumarins as new multitarget antiproliferative agents: Synthesis, biological evaluation and in silico calculations.

Lagunes I, Begines P, Silva A, Galán AR, Puerta A, Fernandes MX, Maya I, Fernández-Bolaños JG, López Ó, Padrón JM.

Eur J Med Chem. 2019 Oct 1;179:493-501. doi: 10.1016/j.ejmech.2019.06.073. Epub 2019 Jun 27.

PMID:
31271961
3.

CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.

Dinić J, Ríos-Luci C, Karpaviciene I, Cikotiene I, Fernandes MX, Pešić M, Padrón JM.

Invest New Drugs. 2019 Jun 8. doi: 10.1007/s10637-019-00803-6. [Epub ahead of print]

PMID:
31177401
4.

Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus.

Rodriguez-Rodriguez AE, Donate-Correa J, Rovira J, Cuesto G, Luis-Ravelo D, Fernandes MX, Acevedo-Arozena A, Diekmann F, Acebes A, Torres A, Porrini E.

Am J Transplant. 2019 Dec;19(12):3240-3249. doi: 10.1111/ajt.15483. Epub 2019 Jul 8.

PMID:
31152486
5.

Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.

Moya-Garzón MD, Martín Higueras C, Peñalver P, Romera M, Fernandes MX, Franco-Montalbán F, Gómez-Vidal JA, Salido E, Díaz-Gavilán M.

J Med Chem. 2018 Aug 23;61(16):7144-7167. doi: 10.1021/acs.jmedchem.8b00399. Epub 2018 Aug 6.

PMID:
30028141
6.

DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.

Podolski-Renić A, Banković J, Dinić J, Ríos-Luci C, Fernandes MX, Ortega N, Kovačević-Grujičić N, Martín VS, Padrón JM, Pešić M.

Eur J Pharm Sci. 2017 Jul 15;105:159-168. doi: 10.1016/j.ejps.2017.05.011. Epub 2017 May 11.

PMID:
28502672
7.

Phosphorylation of Mineralocorticoid Receptor Ligand Binding Domain Impairs Receptor Activation and Has a Dominant Negative Effect over Non-phosphorylated Receptors.

Jiménez-Canino R, Fernandes MX, Alvarez de la Rosa D.

J Biol Chem. 2016 Sep 2;291(36):19068-78. doi: 10.1074/jbc.M116.718395. Epub 2016 Jul 15.

8.

Optimizing the macrocyclic diterpenic core toward the reversal of multidrug resistance in cancer.

Baptista R, Ferreira RJ, Dos Santos DJ, Fernandes MX, Ferreira MJ.

Future Med Chem. 2016 Apr;8(6):629-45. doi: 10.4155/fmc.16.11.

PMID:
27105294
9.

Synthesis and identification of unprecedented selective inhibitors of CK1ε.

Silveira-Dorta G, Sousa IJ, Fernandes MX, Martín VS, Padrón JM.

Eur J Med Chem. 2015;96:308-17. doi: 10.1016/j.ejmech.2015.03.046. Epub 2015 Apr 14.

PMID:
25899335
10.

Dual-stage triterpenoids from an African medicinal plant targeting the malaria parasite.

Ramalhete C, da Cruz FP, Mulhovo S, Sousa IJ, Fernandes MX, Prudêncio M, Ferreira MJ.

Bioorg Med Chem. 2014 Aug 1;22(15):3887-90. doi: 10.1016/j.bmc.2014.06.019. Epub 2014 Jun 18.

PMID:
25002232
11.

Molecular docking studies of the interaction between propargylic enol ethers and human DNA topoisomerase IIα.

Silveira-Dorta G, Sousa IJ, Ríos-Luci C, Martín VS, Fernandes MX, Padrón JM.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5382-4. doi: 10.1016/j.bmcl.2013.07.055. Epub 2013 Jul 31.

PMID:
23953196
12.

Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.

Leão M, Pereira C, Bisio A, Ciribilli Y, Paiva AM, Machado N, Palmeira A, Fernandes MX, Sousa E, Pinto M, Inga A, Saraiva L.

Biochem Pharmacol. 2013 May 1;85(9):1234-45. doi: 10.1016/j.bcp.2013.01.032. Epub 2013 Feb 18.

PMID:
23428467
13.

Sulfated small molecules targeting eBV in Burkitt lymphoma: from in silico screening to the evidence of in vitro effect on viral episomal DNA.

Lima RT, Seca H, Palmeira A, Fernandes MX, Castro F, Correia-da-Silva M, Nascimento MS, Sousa E, Pinto M, Vasconcelos MH.

Chem Biol Drug Des. 2013 May;81(5):631-44. doi: 10.1111/cbdd.12109. Epub 2013 Apr 4.

PMID:
23350710
14.

QSAR studies of macrocyclic diterpenes with P-glycoprotein inhibitory activity.

Sousa IJ, Ferreira MJ, Molnár J, Fernandes MX.

Eur J Pharm Sci. 2013 Feb 14;48(3):542-53. doi: 10.1016/j.ejps.2012.11.012. Epub 2012 Dec 7.

PMID:
23228414
15.
16.

Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective.

Palmeira A, Sousa E, Vasconcelos MH, Pinto M, Fernandes MX.

Curr Pharm Des. 2012;18(27):4197-214. Review.

PMID:
22827485
17.

Multidrug resistance reversal effects of aminated thioxanthones and interaction with cytochrome P450 3A4.

Palmeira A, Sousa E, Fernandes MX, Pinto MM, Vasconcelos MH.

J Pharm Pharm Sci. 2012;15(1):31-45.

18.

Dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones.

Palmeira A, Vasconcelos MH, Paiva A, Fernandes MX, Pinto M, Sousa E.

Biochem Pharmacol. 2012 Jan 1;83(1):57-68. doi: 10.1016/j.bcp.2011.10.004. Epub 2011 Oct 22.

PMID:
22044878
19.

Comparative QSAR analyses of competitive CYP2C9 inhibitors using three-dimensional molecular descriptors.

Lather V, Fernandes MX.

Chem Biol Drug Des. 2011 Jul;78(1):112-23. doi: 10.1111/j.1747-0285.2011.01106.x. Epub 2011 May 26.

PMID:
21477091
20.

New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors.

Palmeira A, Rodrigues F, Sousa E, Pinto M, Vasconcelos MH, Fernandes MX.

Chem Biol Drug Des. 2011 Jul;78(1):57-72. doi: 10.1111/j.1747-0285.2011.01089.x. Epub 2011 Mar 29.

PMID:
21235729

Supplemental Content

Loading ...
Support Center